SG151200A1 - New addition salts of angiotensin-converting enzyme inhibitors with no donor acids, a process for their preparation and pharmaceutical compositions containing them - Google Patents

New addition salts of angiotensin-converting enzyme inhibitors with no donor acids, a process for their preparation and pharmaceutical compositions containing them

Info

Publication number: SG151200A1
Authority: SG; Singapore
Prior art keywords: angiotensin; converting enzyme; preparation; pharmaceutical compositions; addition salts
Prior art date: 2007-09-21

Application number

SG200806674-8A

Other languages

English (en)

Inventor

Guillaume De Nanteuil

Bernard Portevin

Philippe Gloanec

Jean-Gilles Parmentier

Alain Benoist

Tony Verbeuren

Alain Rupin

Christine Courchay

Serge Simonet

Original Assignee

Servier Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-09-21

Filing date

2008-09-11

Publication date

2009-04-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39539691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG151200(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-09-11 Application filed by Servier Lab filed Critical Servier Lab

2009-04-30 Publication of SG151200A1 publication Critical patent/SG151200A1/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
- C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Toxicology (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

SG200806674-8A 2007-09-21 2008-09-11 New addition salts of angiotensin-converting enzyme inhibitors with no donor acids, a process for their preparation and pharmaceutical compositions containing them SG151200A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0706629A FR2921365B1 (fr)	2007-09-21	2007-09-21	Nouveaux sels d'addition d'inhibiteurs d'enzyme de conversion de l'angiotensine a des acides donneurs de no, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number	Publication Date
SG151200A1 true SG151200A1 (en)	2009-04-30

Family

ID=39539691

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG200806674-8A SG151200A1 (en)	2007-09-21	2008-09-11	New addition salts of angiotensin-converting enzyme inhibitors with no donor acids, a process for their preparation and pharmaceutical compositions containing them

Country Status (43)

Country	Link
US (1)	US7981920B2 (es)
EP (2)	EP2236495A1 (es)
JP (1)	JP4903187B2 (es)
KR (1)	KR101070056B1 (es)
CN (1)	CN101391973A (es)
AP (1)	AP2010005204A0 (es)
AR (1)	AR068488A1 (es)
AT (1)	ATE476416T1 (es)
AU (1)	AU2008217013B8 (es)
BR (1)	BRPI0804073A2 (es)
CA (1)	CA2639700C (es)
CL (1)	CL2008002725A1 (es)
CR (1)	CR11320A (es)
CY (1)	CY1110782T1 (es)
DE (1)	DE602008002027D1 (es)
DK (1)	DK2039682T3 (es)
EA (1)	EA015092B1 (es)
EC (1)	ECSP10010040A (es)
ES (1)	ES2349493T3 (es)
FR (1)	FR2921365B1 (es)
GE (1)	GEP20125479B (es)
HN (1)	HN2010000533A (es)
HR (1)	HRP20100545T1 (es)
JO (1)	JO2664B1 (es)
MA (1)	MA30320B1 (es)
MX (1)	MX2008011954A (es)
MY (1)	MY144927A (es)
NI (1)	NI201000038A (es)
NZ (1)	NZ572988A (es)
PA (1)	PA8796701A1 (es)
PE (1)	PE20091190A1 (es)
PL (1)	PL2039682T3 (es)
PT (1)	PT2039682E (es)
RS (1)	RS51433B (es)
SA (1)	SA08290599B1 (es)
SG (1)	SG151200A1 (es)
SI (1)	SI2039682T1 (es)
SV (1)	SV2010003511A (es)
TN (1)	TN2010000111A1 (es)
TW (1)	TWI370118B (es)
UY (1)	UY31339A1 (es)
WO (1)	WO2009074733A2 (es)
ZA (1)	ZA200808062B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2961105B1 (fr)	2010-06-15	2013-02-08	Servier Lab	Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
WO2013185124A1 (en) *	2012-06-08	2013-12-12	Wisconsin Alumni Research Foundation	Antimicrobial compounds, compositions and methods of use thereof
CN103848795B (zh) *	2014-03-07	2016-08-17	山东大学	一种1,2,5-噁二唑-2-氧化物组蛋白去乙酰化酶抑制剂及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4218582A1 (de) *	1992-06-05	1993-12-09	Cassella Ag	Pyridyl-1,2,5-oxadiazol-carbonamid-2-oxide
IT1295694B1 (it) *	1996-11-14	1999-05-27	Nicox Sa	Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
WO2000012110A2 (en) *	1998-08-26	2000-03-09	Queen's University At Kingston	Use of anti(w)pressor agents for vascular remodeling in genital dysfunction
DE10033580A1 (de)	2000-04-10	2001-10-11	Bayer Ag	Verfahren zur Herstellung von Ditaurin und seinen Salzen
AUPS236902A0 (en) *	2002-05-16	2002-06-13	Northern Sydney Area Health Service	Composition and method for treating hypertension
AU2003286389A1 (en) *	2002-11-29	2004-06-23	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Ace-inhibitors having antioxidant and nitricoxid-donor activity
JP2007502831A (ja) *	2003-08-20	2007-02-15	ニトロメッドインコーポレーティッド	ニトロソ化およびニトロシル化心血管化合物、組成物、ならびに使用方法
CA2595579A1 (en) *	2005-01-21	2006-07-27	Nitromed, Inc.	Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use
EP1877374A1 (en) *	2005-03-18	2008-01-16	Nitromed, Inc.	Organic nitric oxide enhancing salts of angiotensin converting enzyme inhibitors, compositions and methods of use
RU2271202C1 (ru) *	2005-05-04	2006-03-10	Михаил Владимирович Покровский	Способ коррекции эндотелиальной дисфункции
WO2007016136A2 (en) *	2005-07-28	2007-02-08	Nitromed, Inc.	Organic nitric oxide enhancing salts of cyclooxygenase-2 selective inhibitors, compositons and methods of use
EP1954685A4 (en) *	2005-11-16	2009-11-11	Nitromed Inc	FUROXANE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
US20080293781A1 (en) *	2005-11-23	2008-11-27	Alberto Gasco	Salicylic Acid Derivatives

2007
- 2007-09-21 FR FR0706629A patent/FR2921365B1/fr not_active Expired - Fee Related
2008
- 2008-09-11 SG SG200806674-8A patent/SG151200A1/en unknown
- 2008-09-12 PE PE2008001592A patent/PE20091190A1/es not_active Application Discontinuation
- 2008-09-12 CL CL2008002725A patent/CL2008002725A1/es unknown
- 2008-09-12 UY UY31339A patent/UY31339A1/es unknown
- 2008-09-15 AU AU2008217013A patent/AU2008217013B8/en not_active Ceased
- 2008-09-16 MY MYPI20083604A patent/MY144927A/en unknown
- 2008-09-16 GE GEAP200810907A patent/GEP20125479B/en unknown
- 2008-09-16 MA MA31244A patent/MA30320B1/fr unknown
- 2008-09-17 US US12/283,928 patent/US7981920B2/en not_active Expired - Fee Related
- 2008-09-18 CN CNA2008102131384A patent/CN101391973A/zh active Pending
- 2008-09-18 JO JO2008417A patent/JO2664B1/en active
- 2008-09-19 EP EP10075301A patent/EP2236495A1/fr not_active Withdrawn
- 2008-09-19 TW TW097136239A patent/TWI370118B/zh not_active IP Right Cessation
- 2008-09-19 AR ARP080104074A patent/AR068488A1/es unknown
- 2008-09-19 DK DK08290885.6T patent/DK2039682T3/da active
- 2008-09-19 WO PCT/FR2008/001311 patent/WO2009074733A2/fr not_active Ceased
- 2008-09-19 AP AP2010005204A patent/AP2010005204A0/xx unknown
- 2008-09-19 ZA ZA200808062A patent/ZA200808062B/xx unknown
- 2008-09-19 RS RSP-2010/0403A patent/RS51433B/sr unknown
- 2008-09-19 PA PA20088796701A patent/PA8796701A1/es unknown
- 2008-09-19 AT AT08290885T patent/ATE476416T1/de active
- 2008-09-19 JP JP2008240538A patent/JP4903187B2/ja not_active Expired - Fee Related
- 2008-09-19 PT PT08290885T patent/PT2039682E/pt unknown
- 2008-09-19 EP EP08290885A patent/EP2039682B1/fr active Active
- 2008-09-19 MX MX2008011954A patent/MX2008011954A/es active IP Right Grant
- 2008-09-19 KR KR1020080092197A patent/KR101070056B1/ko not_active Expired - Fee Related
- 2008-09-19 DE DE602008002027T patent/DE602008002027D1/de active Active
- 2008-09-19 SI SI200830064T patent/SI2039682T1/sl unknown
- 2008-09-19 PL PL08290885T patent/PL2039682T3/pl unknown
- 2008-09-19 ES ES08290885T patent/ES2349493T3/es active Active
- 2008-09-19 EA EA200801863A patent/EA015092B1/ru not_active IP Right Cessation
- 2008-09-21 SA SA8290599A patent/SA08290599B1/ar unknown
- 2008-09-22 BR BRPI0804073-7A patent/BRPI0804073A2/pt not_active IP Right Cessation
- 2008-09-22 CA CA2639700A patent/CA2639700C/fr not_active Expired - Fee Related
- 2008-11-20 NZ NZ572988A patent/NZ572988A/en not_active IP Right Cessation
2010
- 2010-03-15 TN TNP2010000111A patent/TN2010000111A1/fr unknown
- 2010-03-17 EC EC2010010040A patent/ECSP10010040A/es unknown
- 2010-03-17 CR CR11320A patent/CR11320A/es not_active Application Discontinuation
- 2010-03-18 SV SV2010003511A patent/SV2010003511A/es not_active Application Discontinuation
- 2010-03-19 HN HN2010000533A patent/HN2010000533A/es unknown
- 2010-03-19 NI NI201000038A patent/NI201000038A/es unknown
- 2010-09-15 CY CY20101100834T patent/CY1110782T1/el unknown
- 2010-10-05 HR HR20100545T patent/HRP20100545T1/hr unknown

Also Published As

Publication number	Publication date
EA200801863A1 (ru)	2009-04-28
DE602008002027D1 (de)	2010-09-16
ES2349493T3 (es)	2011-01-04
RS51433B (sr)	2011-04-30
EA015092B1 (ru)	2011-06-30
EP2039682A1 (fr)	2009-03-25
US7981920B2 (en)	2011-07-19
WO2009074733A3 (fr)	2009-08-20
UY31339A1 (es)	2008-10-31
FR2921365A1 (fr)	2009-03-27
MX2008011954A (es)	2009-03-20
AP2010005204A0 (en)	2010-04-30
FR2921365B1 (fr)	2012-10-12
CY1110782T1 (el)	2015-06-10
SV2010003511A (es)	2010-07-29
SA08290599B1 (ar)	2011-05-04
NZ572988A (en)	2010-07-30
AU2008217013B8 (en)	2012-10-04
AR068488A1 (es)	2009-11-18
PE20091190A1 (es)	2009-08-09
JO2664B1 (en)	2012-06-17
TN2010000111A1 (fr)	2011-09-26
TWI370118B (en)	2012-08-11
JP4903187B2 (ja)	2012-03-28
HRP20100545T1 (hr)	2010-11-30
MA30320B1 (fr)	2009-04-01
SI2039682T1 (sl)	2010-10-29
ATE476416T1 (de)	2010-08-15
PT2039682E (pt)	2010-09-27
DK2039682T3 (da)	2010-11-08
CL2008002725A1 (es)	2009-06-12
WO2009074733A2 (fr)	2009-06-18
PL2039682T3 (pl)	2010-10-29
AU2008217013A1 (en)	2009-04-09
PA8796701A1 (es)	2009-09-17
CA2639700C (fr)	2012-08-28
GEP20125479B (en)	2012-04-25
BRPI0804073A2 (pt)	2009-06-16
US20090082393A1 (en)	2009-03-26
TW200920352A (en)	2009-05-16
AU2008217013A8 (en)	2012-10-04
CN101391973A (zh)	2009-03-25
EP2236495A1 (fr)	2010-10-06
ZA200808062B (en)	2009-11-25
NI201000038A (es)	2010-07-15
MY144927A (en)	2011-11-30
HN2010000533A (es)	2013-07-08
ECSP10010040A (es)	2010-04-30
JP2009137935A (ja)	2009-06-25
AU2008217013B2 (en)	2012-08-16
KR20090031298A (ko)	2009-03-25
CR11320A (es)	2010-06-29
KR101070056B1 (ko)	2011-10-04
EP2039682B1 (fr)	2010-08-04
CA2639700A1 (fr)	2009-03-21

Publication	Publication Date	Title
CY1125155T1 (el)	2023-01-05	Κρυσταλλικες μορφες αναστολεα προλυλο υδροξυλασης
UY32062A (es)	2010-03-26	Inhibidores de beta-secretasa
MY150778A (en)	2014-02-28	Fused heterocyclic compound
MX2009004984A (es)	2009-09-23	Metodos para conservar la funcion renal utilizando inhibidores de oxidoreductasa de xantina.
PH12012500519A1 (en)	2012-10-22	Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors
PT2178881E (pt)	2013-12-26	Novos derivados de 6-triazolopiridazina-sulfanil benzotiazole e benzimidazole, seu método de preparação, sua aplicação como medicamentos, composições farmacêuticas e nova utilização como inibidores de met
MX2013005533A (es)	2013-07-03	Derivados de acido amino-bisfenil-pentanoico sustituidos como inhibidores de nep.
TR201203989T1 (tr)	2012-09-21	Ksantin oksidaz inhibitörleri olarak etkin olan yeni bileşikler, bunları hazırlamaya yönelik yöntem ve bunları içeren farmasötik bileşim.
UA105229C2 (uk)	2014-04-25	Фармацевтичний склад
NZ607600A (en)	2015-05-29	Compositions for the treatment of diseases
WO2008086122A3 (en)	2008-10-16	Imidazole derivatives as kinesin spindle protein inhibitors (eg-5)
EA200401079A1 (ru)	2005-06-30	Пестицидная композиция, содержащая эфир молочной кислоты в качестве ингибитора роста кристаллов
WO2011047055A3 (en)	2011-08-18	Novel mek inhibitors, useful in the treatment of diseases
UA112556C2 (uk)	2016-09-26	Інсектицидні похідні 2-метоксибензамідів
MX2009007265A (es)	2009-07-10	Sales, composiciones liquidas acuosas que cotienen sales de acido s-(+)-abscisico y metodos para su preparacion.
BRPI0709772B8 (pt)	2021-05-25	sais de malato e polimorfos do ácido (3s,5s)-7-[3-amino-5-metil-piperidinil]-1-ciclopropil-1,4-diidro-8-metóxi-4-oxo-3-quinolinocarboxílico
TW200716138A (en)	2007-05-01	Stable active compound complex of salts of O-acetylsalicylic acid with basic amino acids and glycine
SG151200A1 (en)	2009-04-30	New addition salts of angiotensin-converting enzyme inhibitors with no donor acids, a process for their preparation and pharmaceutical compositions containing them
AR075097A1 (es)	2011-03-09	Sales y formas polimorficas cristalinas de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonil urea, composiciones farmaceuticas que las contiene, metodo para prepararlas y uso de las mismas en el tratamiento de enfermedades cardiovasculares asocia
HRP20191159T1 (hr)	2019-10-04	Prolijekovi nmda antagonista
MY163513A (en)	2017-09-15	Liquid detergent composition
WO2007132478A3 (en)	2009-06-04	Process for the preparation of pure risedronic acid or salts
EA200800464A1 (ru)	2008-08-29	Фармацевтическая композиция, содержащая периндоприл или его соли
WO2011159471A3 (en)	2012-04-12	Linked purine pterin hppk inhibitors useful as antibacterial agents
EA201190078A1 (ru)	2012-02-28	Композиции и способы блокирования реакции на этилен у полевых культур с помощью натриевой соли 3-циклопропил-1-енилпропионовой кислоты